An article reporting the first xenotransplantation of a pig liver into a human has been published in the  Nature. The xenotransplant took place in China on March 10, 2024.

The recipient was a 50-year-old brain-dead man who received a genetically modified pig liver that remained functioning for 10 days until the patient’s family decided to end the experiment.

The transplanted liver had six genetic modifications that facilitated compatibility with the recipient and thus prevented organ rejection. The patient was also given immunosuppressants.

The patient did not suffer from any liver problems, and his liver remained in place, while the new organ was transplanted elsewhere in the abdomen. During the ten days it was implanted, the porcine liver produced bile and albumin.

This xenotransplant has served to demonstrate that the pig organ not only functions, but can also serve as a “bridge graft,” meaning it could be temporarily transplanted after fulminant liver failure while awaiting the arrival of a compatible human liver for transplantation.

In some countries, there is a shortage of human organs for transplantation or there is no established transplant program at all. Furthermore, liver donors for transplantation are increasingly older, and the organs arrive in poorer condition.

Other cases of xenotransplantation

The first case of a pig kidney transplant to a brain-dead woman was performed on September 25, 2021, and the organ functioned properly and autonomously for 54 hours.

Subsequently, in January 2022, the first transplant of a pig heart was performed, which was genetically modified to facilitate organ compatibility and reduce the immune rejection response of the patient, who survived two months with severe heart failure.

In 2024, another pig kidney xenotransplant was performed, but this time on a living, but seriously ill, patient who died two months after surgery.

Bioethical Assessment

The difficulty in obtaining human organs for transplantation has prompted research into alternative ways that can help meet the demand for organs. The difficulties involved in transplantation medicine are many, ranging from clinical to legal and economic.

Proposing legislation like the Spanish one, which expands the possibility of obtaining donors provides a strong incentive for the expansion of transplants.

Other difficulties must be overcome, such as providing technical, human, logistical and economic infrastructure to the services involved, to make transplants viable on a larger scale, sufficient to meet the growing demand for organs.

To try to alleviate the shortage of organs for transplant, the creation of organoids in the laboratory, regenerative therapies with stem cells, and the use of animal organs (xenotransplants or human-animal chimeras) have been developed. In this case, the additional difficulties posed by genetic incompatibility due to the different species involved must be overcome.

Gene editing techniques have been applied in these cases to try to alleviate this incompatibility, modifying genes related to the immune rejection process by the recipient. This could expand the possibility of obtaining animal organs suitable for human transplantation after gene editing.

However, current results place this possibility still far away. The complexity of genetic modification means that neither animal organs nor “humanized” animal embryos designed to improve their histocompatibility meet the safety and efficacy requirements for application in humans.

Experiments with brain-dead patients raise unresolved ethical difficulties, and their results are limited. Experiments involving living patients have yielded very short survival rates, given the difficulties already mentioned.

Gene editing offers the possibility of adapting animal organs to make them compatible with human recipients, as well as producing new organs from humanized embryos or chimeras. However, the associated risks are also enormous.

Limited knowledge of how our genome works makes it impossible to predict the consequences of editing genes involved in histocompatibility processes.

Although significant progress is being made in this field, the unintended effects associated with modifying certain genes and their interaction with the rest of the genome limit the extent and results of these experiments.

Julio Tudela and Ester Bosch

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

 

Share This Story, Choose Your Platform!